10 Biotechnology Stocks to Sell Now

CVM, EPRS, OHRP, TSRX, VICL, TENX, SGYP, VSTM, CLDX, TRVN slump in weekly rankings

This week, the overall grades of 10 biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

CEL-SCI Corporation’s (CVM) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. To get an in-depth look at CVM, get Portfolio Grader’s complete analysis of CVM stock.

EPIRUS Biopharmaceuticals, Inc.’s (EPRS) rating weakens this week, dropping to a D versus last week’s C. The stock also rates an F in Earnings Revisions. Shares of the stock are being traded at a very rapid pace, up 455.8% from the week prior. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

Ohr Pharmaceutical Inc (OHRP) is having a tough week. The company’s rating falls from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. Trade volume is up 2789.5% from the previous week. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc. (TSRX) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

The rating of Vical Incorporated (VICL) slips from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.

Tenax Therapeutics, Inc. (TENX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TENX stock.

Synergy Pharmaceuticals, Inc. (SGYP) earns an F this week, moving down from last week’s grade of D. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of July 15, 2015, 20.5% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.

This week, Verastem, Inc.’s (VSTM) rating worsens to an F from the company’s D rating a week ago. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of July 15, 2015, 11.6% of outstanding Verastem, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

Celldex Therapeutics, Inc. (CLDX) is having a tough week. The company’s rating falls from a C to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of July 15, 2015, 16.7% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.

The rating of Trevena, Inc. (TRVN) declines this week from a C to a D. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/10-biotechnology-stocks-to-sell-now-cvm-eprs-ohrp-10/.

©2019 InvestorPlace Media, LLC